MK-2866 Ostarine 20mg – 50 Tablets

MK-2866, commonly known as Ostarine or Enobosarm, is the most extensively clinically studied SARM in current research literature having progressed through multiple Phase II clinical trials examining cancer related muscle wasting and cachexia, and currently advancing through Phase III trials for indications including stress urinary incontinence and ER+ breast cancer, contributing the largest human clinical dataset of any SARM compound. F40 Biotech’s formulation delivers 20mg per tablet in a 50 count format, consistent with the upper end of the dose range most frequently referenced in Ostarine clinical trial literature.

Ostarine’s clinical development history distinguishes it meaningfully from LGD-4033, S23, and YK-11 within CSD’s SARM range. While all share the broad non steroidal tissue selective androgen receptor activation principle, Ostarine’s clinical trials have generated documented data on lean body mass increases in elderly and cachectic patient populations with comparatively favorable tolerability findings relative to other SARM compounds at clinically studied doses. A research distinction that has made it the most frequently referenced reference compound in comparative SARM tolerability and efficacy research. Its relatively mild HPG axis suppression profile at lower research doses compared to higher affinity compounds like S23 has additionally generated specific interest in dose response studies examining the relationship between androgen receptor binding affinity and the magnitude of endogenous testosterone suppression across the SARM compound class.

Ostarine’s mechanism follows the same non steroidal androgen receptor binding principle shared across true SARMs, avoiding 5-alpha reductase and aromatase enzyme interaction while activating downstream anabolic signaling preferentially in muscle and bone tissue. Its pharmacokinetic profile includes a half-life of approximately 24 hours, supporting once daily research administration consistent with the dosing schedules referenced in its clinical trial protocols. This combination of extensive clinical documentation and comparatively well characterized tolerability has positioned Ostarine as the most frequently used reference compound in academic and industry sponsored comparative SARM research.

F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s MK-2866 meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store in a cool, dry place away from direct light and heat. Intended for research purposes only.

Commonly researched alongside LGD-4033 and S23 in comparative SARM clinical trial data and receptor binding affinity studies. Browse CSD’s full SARM range for complete sourcing.